Related references
Note: Only part of the references are listed.A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study
Polina Putrik et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
Rajendrakumar H. Jani et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2016)
Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists
Petra Baji et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2016)
Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea
Seoyoung C. Kim et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Nomenclature and Traceability Debate for Biosimilars: Small-Molecule Surrogates Lend Support for Distinguishable Nonproprietary Names
Jingdong Chao et al.
ADVANCES IN THERAPY (2015)
The Budget Impact of Biosimilar Infliximab (Remsima(A (R))) for the Treatment of Autoimmune Diseases in Five European Countries
Ashok Jha et al.
ADVANCES IN THERAPY (2015)
A RANDOMISED, DOUBLE-BLIND, PHASE III STUDY COMPARING SB2, AN INFLIXIMAB BIOSIMILAR, TO THE INFLIXIMAB REFERENCE PRODUCT (REMICADE®) IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
J. -Y. Choe et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
Elena Nikiphorou et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Biosimilars for the management of rheumatoid arthritis: economic considerations
Laszlo Gulacsi et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2015)
Japanese regulatory authority's perspective on biosimilars
Sumimasa Nagai et al.
LANCET ONCOLOGY (2015)
Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
Tsutomu Takeuchi et al.
MODERN RHEUMATOLOGY (2015)
Biosimilars in rheumatology: current perspectives and lessons learnt
Thomas Doerner et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?
Polina Putrik et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Inequities in access to biologic and synthetic DMARDs across 46 European countries
Polina Putrik et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Putting the value into biosimilar decision making
Mirhelen Mendes de Abreu et al.
AUTOIMMUNITY REVIEWS (2014)
The challenge of indication extrapolation for infliximab biosimilars
Brian G. Feagan et al.
BIOLOGICALS (2014)
Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database
Paola M. Cutroneo et al.
DRUG SAFETY (2014)
Biosimilars: how similar?
V. Strand et al.
INTERNAL MEDICINE JOURNAL (2014)
Biosimilars entering the clinic without animal studies A paradigm shift in the European Union
Leon A. G. J. M. van Aerts et al.
MABS (2014)
Pharmacoeconomics of Cancer Therapies: Considerations With the Introduction of Biosimilars
David Henry et al.
SEMINARS IN ONCOLOGY (2014)
Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries
Marta Pentek et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
Subsequent entry biologics (biosimilars) in Canada: approaches to interchangeability and the extrapolation of indications and uses
Agnes V. Klein et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2014)
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
Valentin Brodszky et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
Interchangeability. An insurmountable fifth hurdle?
Hans C. Ebbers et al.
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL (2014)
The role of biosimilars in the treatment of rheumatic diseases
Thomas Doerner et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Biosimilars to treat inflammatory arthritis: the challenge of proving identity
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Dae Hyun Yoo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
Won Park et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Traceability of Biopharmaceuticals in Spontaneous Reporting Systems: A Cross-Sectional Study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance Databases
Niels S. Vermeer et al.
DRUG SAFETY (2013)
Clinical experience with ZarzioA® in Europe: what have we learned?
Pere Gascon et al.
SUPPORTIVE CARE IN CANCER (2013)
INTRODUCTION OF AN INFLIXIMAB BIOSIMILAR (CT-P13): A FIVE-YEAR BUDGET IMPACT ANALYSIS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN IRELAND
G. McCarthy et al.
VALUE IN HEALTH (2013)
Does Value Mean Quality? The Payer's Perspective
Jennifer L. Malin
JOURNAL OF ONCOLOGY PRACTICE (2013)
The safety of switching between therapeutic proteins
Hans C. Ebbers et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
The economic pressures for biosimilar drug use in cancer medicine
Paul Cornes
TARGETED ONCOLOGY (2012)
Experience of reviewing the follow-on biologics including Somatropin and erythropoietin in Japan
Teruyo Arato et al.
BIOLOGICALS (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Clinical comparability and European biosimilar regulations
Huub Schellekens et al.
NATURE BIOTECHNOLOGY (2010)
Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database
T. Sokka et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Peter B. Bach
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
